Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels
Authors: Naomi Schlesinger
Journal: Annals of Internal Medicine (2019)

Letters21 May 2019Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid LevelsNaomi Schlesinger, MDNaomi Schlesinger, MDRutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey (N.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0123 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I read Solomon and colleagues' article (1) with interest. Gout is perceived as an acute disease that only requires treatment for acute attacks. However, long-term urate-lowering therapy that reduces serum uric acid levels to below the saturation threshold (404.5 µmol/L) and long-term anti-inflammatory prophylaxis (especially while urate-lowering therapy is being initiated) are needed to combat this condition.Another article by Solomon and colleagues (2) discusses the use of interleukin-1β (Il-1β) inhibition for prophylaxis of chronic gout. It focuses on Il-1β, a proinflammatory cytokine that plays a key role in gouty inflammation and contributes to bone erosions and ...References1. Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169:535-42. [PMID: 30242335]. doi:10.7326/M18-1167 LinkGoogle Scholar2. Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Serum urate, gout, and cardiovascular disease in a randomized controlled trial of canakinumab: a CANTOS secondary analysis. Ann Rheum Dis. 2018;77:56-7. Google Scholar3. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. [PMID: 28845751] doi:10.1056/NEJMoa1707914 CrossrefMedlineGoogle Scholar4. Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70:1264-71. [PMID: 21540198] doi:10.1136/ard.2010.144063 CrossrefMedlineGoogle Scholar5. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71:1839-48. [PMID: 22586173] doi:10.1136/annrheumdis-2011-200908 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey (N.S.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0123. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRelationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels Daniel H. Solomon , Robert J. Glynn , Jean G. MacFadyen , Peter Libby , Tom Thuren , Brendan M. Everett , and Paul M Ridker Metrics Cited byAssociations of habitual glucosamine supplementation with incident gout: a large population based cohort studyCardiovascular safety risks associated with gout treatments 21 May 2019Volume 170, Issue 10Page: 737-738KeywordsCardiovascular disease riskCardiovascular diseasesDisclosureGoutInflammationMonoclonal antibodiesMyocardial infarctionProphylaxisThrombosisUric acid ePublished: 21 May 2019 Issue Published: 21 May 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...